AI tools for predicting high-risk coronary plaques
Official title: Rustworthy, Integrated Artificial Intelligence Tools for Predicting High-risk CORonary PlaqueS
Run by Centro Cardiologico Monzino · NCT06410690 · Data updated 2026-11-12
This study is testing a new AI tool to see if it can better predict dangerous plaque buildup in the arteries of people with heart disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 4000 (estimated) |
| Sponsor | Centro Cardiologico Monzino Academic / other |
| Locations | 2 sites (Milan, Milan and 1 other locations) |
| Status | Recruiting |
| Started | May 22, 2023 |
| Main results expected | November 30, 2026 |
| Study ends | November 30, 2026 |
| Registry record updated | May 29, 2026 |
| Trial ID | NCT06410690 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with known or suspected CAD who are referred for diagnostic evaluation using advanced CCTA technology.
✕Probably not a fit
Patients with low-to-intermediate likelihood of CAD, acute coronary syndrome, or other specific exclusions such as pregnancy or certain cardiac conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to develop an integrated artificial intelligence model to assess and predict high-risk coronary plaques in patients with suspected or known coronary artery disease (CAD). It will utilize a retrospective cohort of patients who have undergone coronary computed tomography angiography (CCTA) to create a decision model that incorporates machine learning and computational analysis. The goal is to improve risk stratification and identify patients at higher risk for cardiovascular events more accurately than current methods. The study will validate the AI tools against established standards to ensure their reliability and effectiveness.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the ability to predict cardiovascular events in high-risk patients, leading to better management and outcomes.
How similar studies have gone: Other studies utilizing AI for cardiovascular risk assessment have shown promise, indicating that this approach may lead to meaningful advancements in patient care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients (age ≥ 18 years) with known or suspected CAD referred for clinically indicated diagnostic evaluation; * CCTA performed with state-of-the-art scanner technology, i.e., scanners with more than 64 slices. Exclusion Criteria: * performance of any non-invasive diagnostic test within 90 days before enrolment; * low-to-intermediate pre-test likelihood of CAD according to the updated Diamond-Forrester risk model score; * acute coronary syndrome; * evidence of clinical instability; * contraindication to contrast agent administration and/or impaired renal function; * inability to sustain a breath hold; * pregnancy; * cardiac arrhythmias;- presence of a pacemaker or implantable cardioverter defibrillator; * contraindications to the administration of sublingual nitrates, β-blockers or adenosine; * structural cardiomyopathy
Where it's running
-
Centro Cardiologico Monzino
Milan, Milan, Italy Recruiting -
Centro Cardiologico Monzino
Milan, Mi, Italy Recruiting
Study contacts
- Study coordinator: Gianluca Pontone
- Email: gianluca.pontone@cardiologicomonzino.it
- Phone: 0258002574
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CCTA-Guided CABG vs CAG-Guided CABG
This study tests whether planning CABG with a non-invasive CCTA scan works as well as planning with the standard invasive CAG approach for people with blocked heart arteries.
-
Comparing heart imaging techniques for coronary artery disease
This study is testing if a new heart imaging method can better identify problems in patients suspected of having coronary artery disease compared to a traditional imaging technique.
-
Short-term high-dose rosuvastatin effects on coronary plaque using photon-counting CT
This trial tests whether a short course of intensified rosuvastatin (40 mg) changes coronary plaque composition and flow on photon‑counting coronary CT in statin‑naive adults with stable chest pain and mild atherosclerosis.
-
Using CCTA to improve management of stable chest pain
This study is testing if using a special heart scan called CCTA can help doctors better manage stable chest pain and reduce serious heart problems for patients suspected of having blocked arteries.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.